Good questions. I didn't look up the actual journal article:
Soman NR, Baldwin SL, Hu G, Marsh JN, Lanza GM, Heuser JE, Arbeit JM, Wickline SA, Schlesinger PH. Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. Journal of Clinical Investigation. August 10, 2009 (advance online publication)
But, I think they functionalized the nanoparticles to be attracted only to the cancer cells and injected the nanoparticles at the site.
My lay person's guess about the BBB is that Mellitin is so potent that the researchers would see increased mortality.